Estela Rodriguez: Key Insights from MaTOS Lung Edition 2026
Estela Rodriguez

Estela Rodriguez: Key Insights from MaTOS Lung Edition 2026

The Masters in Therapeutic Oncology Summit (MaTOS) Lung Edition 2026, taking place from November 19-22 in Half Moon Bay, California, brings together leading experts in thoracic oncology to discuss the latest developments, clinical challenges, and future directions in lung cancer care.

The scientific program explores key areas of lung cancer management, including early detection and screening, molecular profiling, immunotherapy, targeted therapies, and emerging treatment strategies.

Inside MaTOS26: Key Insights from Estela Rodriguez

Throughout the conference, Dr. Estela Rodriguez, Associate Director of Community Outreach in Thoracic Oncology at the University of Miami’s Sylvester Comprehensive Cancer Center, has been sharing insights and key takeaways on X, highlighting important presentations, expert perspectives, and ongoing challenges in lung cancer care.

“MaTOS26 Day 1 Dr Jessica S. Donington starts the meeting w a great discussion on the challenges of lung cancer screening!

20 years after the first I-ELCAP screening publication, we screen only ~24% of eligible individuals, and annual adherence remains below 50%.

How do we close the gap? Better educate primary care, raise public awareness, and simplify the screening process!

Estela Rodriguez

Patricia Rivera makes the case that the future of lung cancer screening lies in a more personalized approach integrating clinical risk assessment and blood-based biomarkers to improve early detection.

Estela Rodriguez: Key Insights from MaTOS Lung Edition 2026

Dr. Jay Lee reviews perioperative chemo-IO and survival outcomes in resectable NSCLC. The shift to induction therapy has happened. What’s missing?

  • Identifying who benefits most,
  • isolating the adjuvant contribution,
  • personalizing surgery vs. chemoradiation in borderline cases.

Estela Rodriguez: Key Insights from MaTOS Lung Edition 2026

Dr. Tina Cascone, the reigning queen of perioperative chemo-IO, takes the stage and makes a compelling case in the debate on ctDNA in early-stage lung cancer (against Hossein Borghaei) for surveillance , clinical trial integration, and guiding treatment escalation or de-escalation.

Estela Rodriguez: Key Insights from MaTOS Lung Edition 2026

Best part of this meeting: multidisciplinary roundtables with experts from across the country, sharing experiences and perspectives where data are limited – from targeted therapies in the perioperative setting to defining borderline-resectable disease.

Grateful to be part of these conversations that move the field forward!

Estela Rodriguez: Key Insights from MaTOS Lung Edition 2026

Dr. Nagla Abdel Karim brings the ‘Habibi’ energy with a spirited and colorful argument against Wade Iams for lurbinectedin over tarlatamab + durvalumab (DeLLphi-305) as maintenance therapy in ES-SCLC. A great debate on the evolving treatment landscape!

Estela Rodriguez: Key Insights from MaTOS Lung Edition 2026

A message to my younger self: One day, you’ll feel completely comfortable presenting a complex case and being ‘grilled’ by some of the best thoracic experts in the country – without breaking a sweat. Trust yourself.

You belong in the room.

Estela Rodriguez: Key Insights from MaTOS Lung Edition 2026

What a treat to meet and listen to the amazing Solange Peters from Ludwig Cancer deliver a keynote on the Next Generation of Immunotherapy! Her energy, passion, and excitement about the incredible pace of innovation in cancer therapy were absolutely contagious. A glimpse into a very exciting future!

Estela Rodriguez: Key Insights from MaTOS Lung Edition 2026

Explore more articles featuring Dr. Estela Rodriguez on OncoDaily.